Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $31,437.68 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,503 shares of the firm's stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $12.56, for a total value of $31,437.68. Following the transaction, the insider now directly owns 161,860 shares in the company, valued at $2,032,961.60. The sale was disclosed in a document filed with the SEC, which is available at this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 15th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $13.95, for a total value of $34,916.85.
• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.65, for a total value of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.17, for a total value of $965,130.57.
• On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total value of $40,922.40.
• On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total value of $229,075.17.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded down $0.04 during mid-day trading on Wednesday, hitting $12.50. 4,813,182 shares of the stock traded hands, compared to its average volume of 4,574,300. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $17.16. The company has a market cap of $2.68 billion, a price-to-earnings ratio of -113.59 and a beta of 0.91. The stock has a fifty day moving average price of $13.85 and a 200-day moving average price of $10.19.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. During the same period in the previous year, the company posted ($0.05) earnings per share. The firm's revenue was up 47.4% on a year-over-year basis. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.11 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the company. Forerunner Ventures Management LLC bought a new stake in Hims & Hers Health in the fourth quarter worth $86,836,000. Vanguard Group Inc. boosted its holdings in Hims & Hers Health by 3.1% in the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company's stock worth $88,857,000 after acquiring an additional 428,671 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Hims & Hers Health by 39.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company's stock worth $8,006,000 after acquiring an additional 357,590 shares in the last quarter. Federated Hermes Inc. boosted its holdings in Hims & Hers Health by 38.6% in the third quarter. Federated Hermes Inc. now owns 1,032,452 shares of the company's stock worth $6,494,000 after acquiring an additional 287,552 shares in the last quarter. Finally, Must Asset Management Inc. bought a new stake in Hims & Hers Health in the third quarter worth $1,596,000. 63.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HIMS has been the topic of a number of analyst reports. Citigroup lifted their price target on Hims & Hers Health from $12.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, February 27th. Seaport Res Ptn reaffirmed a "buy" rating on shares of Hims & Hers Health in a research note on Friday, April 26th. SVB Leerink initiated coverage on Hims & Hers Health in a research note on Monday, February 26th. They set a "market perform" rating and a $10.00 target price on the stock. Canaccord Genuity Group initiated coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They set a "buy" rating and a $20.00 target price on the stock. Finally, Truist Financial boosted their target price on Hims & Hers Health from $10.00 to $13.00 and gave the company a "hold" rating in a research note on Tuesday, February 27th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $14.85.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.